BWM
SPRY icon

Bernard Wealth Management’s ARS Pharmaceuticals SPRY Stock Holding History

Bernard Wealth Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.4K Sell
2,420
-100
-4% -$860 0.01% 193
2026
Q1 		$20.2K Hold
2,520
– – 0.01% 186
2025
Q4 		$29.4K Hold
2,520
– – 0.01% 160
2025
Q3 		$25.3K Hold
2,520
– – 0.01% 171
2025
Q2 		$44K Hold
2,520
– – 0.02% 130
2025
Q1 		$31.7K Hold
2,520
– – 0.02% 153
2024
Q4 		$26.6K Buy
+2,520
New +$35.3K 0.01% 161

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Bernard Wealth Management's SPRY Position: Q2 2026 in Review

Bernard Wealth Management reduced its ARS Pharmaceuticals (SPRY) stake by 4% in Q2 2026, selling an estimated $860 and leaving 2,420 shares worth $19.4K. The position accounts for 0.01% of the portfolio, ranked #193.

Bernard Wealth Management first reported a position in SPRY in Q4 2024 and has held it in 7 quarters since. The position peaked at $44K in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Bernard Wealth Management held 2,420 shares of ARS Pharmaceuticals worth $19.4K as of Q2 2026.
  • Bernard Wealth Management sold 100 ARS Pharmaceuticals shares in Q2 2026, an estimated $860.
  • ARS Pharmaceuticals made up 0.01% of Bernard Wealth Management's portfolio in Q2 2026, its #193 holding.
  • Bernard Wealth Management first reported a position in ARS Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Bernard Wealth Management's ARS Pharmaceuticals position peaked at $44K in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Bernard Wealth Management's 13F filing for Q2 2026, filed 21 Aug 2026.